Fig. 1: Waterfall plots for percentage of tumor reductions.
From: Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Tumor reduction from baseline in patients with BRAFV600E mutation-positive rare cancers by investigator assessment (a) and by independent review (b). MR, minor response; NE, not evaluable; PD, progressive disease; SD, stable disease.
